共 50 条
- [41] CANaspire, a First-in-Human Phase 1/2 Controlled Open-Label Study of BBP-812, a Recombinant AAV9-hASPA Vector for the Treatment of Canavan DiseaseANNALS OF NEUROLOGY, 2022, 92 : S184 - S185Eichler, F.Laforet, G.Andonian, H.Kinane, B.Kirby, K.Nagy, A.Shaywitz, A.Balser, J.Bley, A.
- [42] AAV8 gene therapy as a potential treatment for adults with late-onset ornithine transcarbamylase (OTC) deficiency: updated results from a phase 1/2 clinical trialHUMAN GENE THERAPY, 2021, 32 (19-20) : A9 - A9Geberhiwot, T.Couce, M. L.Hualde, L. C.Harding, C. O.Khan, A.Diaz, G. A.Tan, W.Konczal, L.Thomas, J.Guffon, N.Lee, C.Puga, A. C.Crombez, E.
- [43] AAV8 Gene Therapy as a Potential Treatment in Adults with Late-Onset Ornithine Transcarbamylase (OTC) Deficiency: Updated Results from a Phase 1/2 Clinical TrialMOLECULAR THERAPY, 2021, 29 (04) : 17 - 17Harding, Cary O.Luz Couce, MariaGeberhiwot, TarekegnTan, Wen-HannKhan, AnealAldamiz-Echevarria, LuisDiaz, George A.Lee, ConniePuga, Ana CristinaCrombez, Eric
- [44] Preliminary Safety Data of a Phase 1/2 Clinical Trial to Support the Use of High Dose Intrathecal AAV9/AP4M1 for the Treatment of Patients with SPG50 DiseaseMOLECULAR THERAPY, 2024, 32 (04) : 671 - 671Messahel, SouadChen, XinPirovolakis, TerryCooper, SydneyBoitnott, AndreaSrinivasan, KalayarasanMuthukumar, AlagarGottlieb, KeithFakhari, Darius EbrahimiGray, Steven J.Dowling, JamesIannaccone, Susan
- [45] The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher diseaseMOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S51 - S52Jacobsen, LeslieKerner, Julie A.Ciotti, RachelGolipour, AzadehYang, JosiePfeifer, RichardKhan, AnealMason, Chris
- [46] Translation of AMT-130 Preclinical Data to Inform the Design of the First FDA-approved Human AAV Gene Therapy Clinical Trial in Adults with Early Manifest Huntington's DiseaseNEUROLOGY, 2020, 94 (15)Reilmann, RalfRoss, ChristopherTesta, ClaudiaFrank, SamuelEvers, Melvinde Haan, MartinValles-Sanchez, AstridKonstantinova, Pavlinavan Deventer, SanderHiggins, Joseph
- [47] AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Results from a Phase 1/2 Clinical TrialMOLECULAR THERAPY, 2020, 28 (04) : 558 - 558Weinstein, David A.Ahmad, AyeshaRodriguez-Buritica, David F.Mitchell, JohnDerks, Terry G.Mou, JianiPoma, AllenCrombez, Eric
- [48] SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSACYTOTHERAPY, 2024, 26 (06) : S18 - S18Upadhyay, A. K.Qamar, H.Matloob, S.Chavali, M.
- [49] COHORT 1-4 RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF AN AAV8-MEDIATED LIVER-DIRECTED GENE THERAPY IN ADULTS WITH GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 296 - 296Rodriguez-Buritica, David F.Ahmad, AyeshaPico, Maria-Luz CouceDerks, Terry G.Mitchell, JohnRiba-Wolman, RebeccaWeinstein, David A.Lee, ConnieValayannopoulos, VassiliCrombez, Eric
- [50] Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular DegenerationINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)Nielsen, JaredMacLaren, Robert E.Heier, Jeffrey S.Steel, DavidIvanova, TsvetaSivaprasad, SobhaStanga, PauloBailey, ClareIssa, Peter CharbelMendonca, LuisaFrancis, JamesCurtiss, DarinHughes, JaneWaheed, Nadia K.